Adovate
Biopharmaceutical company focused on discovery and development of selective small-molecule modulators of adenosine receptors. Operates a receptor-focused drug discovery platform combined with medicinal chemistry, receptor pharmacology, preclinical in vivo testing, analytical/CMC support, and collaborations with academic partners to advance candidates into early clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Products
ADO-5030
Clinical-stage small-molecule antagonist selective for the adenosine A2B receptor advanced into clinical development for respiratory and infectious-disease indications.
Adovate Adenosine Drug Development Platform
Proprietary drug development platform used to design patentable compounds targeting adenosine receptors with favorable physiochemical characteristics.
ADO-5030
Clinical-stage small-molecule antagonist selective for the adenosine A2B receptor advanced into clinical development for respiratory and infectious-disease indications.
Adovate Adenosine Drug Development Platform
Proprietary drug development platform used to design patentable compounds targeting adenosine receptors with favorable physiochemical characteristics.
Services
Partnership-based execution of preclinical studies and clinical trials through collaborations with academic clinical sites and research institutions.
Licensing and collaboration opportunities to leverage a platform for designing selective adenosine receptor modulators with optimized biodistribution.
Partnership-based execution of preclinical studies and clinical trials through collaborations with academic clinical sites and research institutions.
Licensing and collaboration opportunities to leverage a platform for designing selective adenosine receptor modulators with optimized biodistribution.
Expertise Areas
- Adenosine receptor pharmacology
- GPCR-focused medicinal chemistry
- Preclinical in vivo efficacy testing and disease models
- Analytical chemistry and method validation
Key Technologies
- GPCR pharmacology and radioligand binding assays
- Small-molecule medicinal chemistry
- In vivo murine and infectious disease models
- Biodistribution optimization and ADME assessment
News & Updates
Awarded $800,000 by Virginia Catalyst to support a Phase 2 clinical trial of the lead A2B receptor antagonist in collaboration with the University of Virginia and Virginia Tech.
Accepted into a global life-sciences incubator network to access resources for scientific and development acceleration.
U.S. patent issued covering next-generation A2B receptor antagonist compositions and the lead compound; patenting expands protection for therapeutic uses including asthma and other indications.
U.S. patent issued covering therapeutic uses of A2B receptor antagonists across multiple disease areas including asthma, cancer and inflammatory conditions.
Settled security interests and encumbrances related to the acquisition of an adenosine drug development platform and associated assets.
Completed a summer internship program with academic and regional partners supporting chemistry, AI workflow and strategy projects.
Awarded $800,000 by Virginia Catalyst to support a Phase 2 clinical trial of the lead A2B receptor antagonist in collaboration with the University of Virginia and Virginia Tech.
Accepted into a global life-sciences incubator network to access resources for scientific and development acceleration.
U.S. patent issued covering next-generation A2B receptor antagonist compositions and the lead compound; patenting expands protection for therapeutic uses including asthma and other indications.
U.S. patent issued covering therapeutic uses of A2B receptor antagonists across multiple disease areas including asthma, cancer and inflammatory conditions.
Settled security interests and encumbrances related to the acquisition of an adenosine drug development platform and associated assets.
Completed a summer internship program with academic and regional partners supporting chemistry, AI workflow and strategy projects.